Although it is hard to ensure equal therapeutic efficacy across all subtypes of AD, such a dual-inhibitor approach represents the most promising therapeutic strategy to benefit the widest range of AD subtypes, particularly considering the biomarker-driven patient selection criteria and the fundamental role of both Aβ and tau in the pathogenesis of AD. This evidence concerns the gene MAPT and Alzheimer disease.